Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abiraterone Acetate

FDA-approved product (tablet, oral), marketed as Abiraterone Acetate, Yonsa, Zytiga.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Abiraterone Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other hormone antagonists and related agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abiraterone Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abiraterone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

    NCT07650240 · start 2026-08-04

    Registered record
    Registry ID
    NCT07650240
    Conditions
    Recurrent Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8; Castration-Sensitive Prostate Cancer; Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Prostate Adenocarcinoma; Adenocarcinoma of the Prostate; Localized Prostate Carcinoma; Metastatic Prostate Cancer; Metastatic Prostate Adenocarcinoma; Advanced Prostate Cancer; Advanced Prostate Adenocarcinoma
    Interventions
    Abiraterone Acetate; Biospecimen Collection; Leuprolide Acetate; Lutetium Lu 177 Vipivotide Tetraxetan; Prednisone; PSMA PET-CT Scan; Quality-of-Life Assessment; Single Photon Emission Computed Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-08-04
    Completion
    2030-12-30
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8; Castration-Sensitive Prostate Cancer; Metastatic Hormone-sensitive Prostate Cancer (mHSPC) +8 more
    InterventionAbiraterone Acetate; Biospecimen Collection; Leuprolide Acetate; Lutetium Lu 177 Vipivotide Tetraxetan +4 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

    NCT06844383 · start 2026-05-04

    Registered record
    Registry ID
    NCT06844383
    Conditions
    Prostate Cancer (Adenocarcinoma); mCRPC (Metastatic Castration-resistant Prostate Cancer)
    Interventions
    Talazoparib with enzalutamide; Talazoparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-04
    Completion
    2030-03
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer (Adenocarcinoma); mCRPC (Metastatic Castration-resistant Prostate Cancer)
    InterventionTalazoparib with enzalutamide; Talazoparib
    PhasePhase 2
    Registry statusRecruiting

  • A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

    NCT07311694 · start 2026-02-02

    Registered record
    Registry ID
    NCT07311694
    Conditions
    PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
    Interventions
    HRS-4357 injection; Enzalutamide；Abiraterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-02-02
    Completion
    2028-12
    Enrolment
    370

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
    InterventionHRS-4357 injection; Enzalutamide；Abiraterone
    PhasePhase 3
    Registry statusRecruiting

  • REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

    NCT06650579 · start 2025-01-31

    Registered record
    Registry ID
    NCT06650579
    Conditions
    Recurrent Prostate Carcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    Interventions
    Abiraterone Acetate; Bicalutamide; Biospecimen Collection; Computed Tomography Angiography; Leuprolide; Prednisone; Radiation Therapy; Relugolix
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-01-31
    Completion
    2029-07-01
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Prostate Carcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    InterventionAbiraterone Acetate; Bicalutamide; Biospecimen Collection; Computed Tomography Angiography +4 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

    NCT06568094 · start 2024-09-25

    Registered record
    Registry ID
    NCT06568094
    Conditions
    Prostate Cancer
    Interventions
    HRS-5041 tablets; Abiraterone Acetate tablets（II）; Prednisone Acetate tablets; Docetaxel Injection; HRS-1167 tablets; SHR2554 tablets; HRS-6208 capsules; HRS-2189 Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-09-25
    Completion
    2027-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionHRS-5041 tablets; Abiraterone Acetate tablets（II）; Prednisone Acetate tablets; Docetaxel Injection +4 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.

    NCT07717268 · start 2024-05-16

    Registered record
    Registry ID
    NCT07717268
    Conditions
    Prostatic Neoplasms, Castration-Resistant
    Interventions
    Xtandi; Zytiga® (Abiraterone Acetate); SBRT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-05-16
    Completion
    2030-05-16
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms, Castration-Resistant
    InterventionXtandi; Zytiga® (Abiraterone Acetate); SBRT
    PhasePhase 2
    Registry statusRecruiting

  • Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    NCT06136624 · start 2023-12-31

    Registered record
    Registry ID
    NCT06136624
    Conditions
    Prostate Cancer Metastatic
    Interventions
    Opevesostat; Abiraterone acetate; Enzalutamide; Hydrocortisone; Fludrocortisone acetate; Prednisone; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-12-31
    Completion
    2030-02-15
    Enrolment
    1,310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionOpevesostat; Abiraterone acetate; Enzalutamide; Hydrocortisone +3 more
    PhasePhase 3
    Registry statusRecruiting

  • Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

    NCT05276492 · start 2023-01-24

    Registered record
    Registry ID
    NCT05276492
    Conditions
    Prostate Cancer; Prostate Adenocarcinoma; Prostate Neoplasm; Prostate Cancer Metastatic
    Interventions
    Abiraterone Oral Tablet; Prednisone tablet; Drug Dairy/Log; Low-fat meal
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2023-01-24
    Completion
    2024-11-16
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Prostate Adenocarcinoma; Prostate Neoplasm; Prostate Cancer Metastatic
    InterventionAbiraterone Oral Tablet; Prednisone tablet; Drug Dairy/Log; Low-fat meal
    PhasePhase 1
    Registry statusTerminated

  • Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

    NCT05212857 · start 2022-04

    Registered record
    Registry ID
    NCT05212857
    Conditions
    Prostate Cancer
    Interventions
    Leuprolide acetate; Goserelin acetate; Triptorelin acetate; Degarelix acetate; Abiraterone acetate; Apalutamide; Enzalutamide; Local treatment for primary lesion; Radiotherapy for primary lesion; Radiotherapy for metastatic lesion
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-04
    Completion
    2024-09
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionLeuprolide acetate; Goserelin acetate; Triptorelin acetate; Degarelix acetate +6 more
    PhasePhase 2
    Registry statusUnknown

  • A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

    NCT05295927 · start 2022-03-23

    Registered record
    Registry ID
    NCT05295927
    Conditions
    Prostatic Neoplasms
    Interventions
    EPI-7386; Abiraterone Acetate; Prednisone or Prednisolone; Apalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2022-03-23
    Completion
    2022-09-30
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionEPI-7386; Abiraterone Acetate; Prednisone or Prednisolone; Apalutamide
    PhasePhase 1
    Registry statusTerminated

  • A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

    NCT05137262 · start 2021-10-13

    Registered record
    Registry ID
    NCT05137262
    Conditions
    Urothelial Carcinoma; Bladder Cancer
    Interventions
    Abiraterone acetate; Durvalumab; Methotrexate; Vinblastine; Doxorubicin Hydrochloride; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-10-13
    Completion
    2028-08-31
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Carcinoma; Bladder Cancer
    InterventionAbiraterone acetate; Durvalumab; Methotrexate; Vinblastine +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

    NCT04812366 · start 2021-09-21

    Registered record
    Registry ID
    NCT04812366
    Conditions
    Prostate Cancer
    Interventions
    Apalutamide 60mg Tab; Abiraterone Acetate 250mg; Prednisone 5mg Tab; Docetaxel; Niraparib 100mg Oral Capsule; Atezolizumab; Tazemetostat Pill; Capivasertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-09-21
    Completion
    2027-06-01
    Enrolment
    315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionApalutamide 60mg Tab; Abiraterone Acetate 250mg; Prednisone 5mg Tab; Docetaxel +4 more
    PhasePhase 2
    Registry statusRecruiting

  • A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

    NCT04869488 · start 2021-07-19

    Registered record
    Registry ID
    NCT04869488
    Conditions
    Metastatic Castration Resistant Prostate Cancer
    Interventions
    Fluzoparib; Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets; Fluzoparib Combined With Apatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-07-19
    Completion
    2023-02-14
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration Resistant Prostate Cancer
    InterventionFluzoparib; Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets; Fluzoparib Combined With Apatinib
    PhasePhase 2
    Registry statusCompleted

  • Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate

    NCT04736108 · start 2021-05

    Registered record
    Registry ID
    NCT04736108
    Conditions
    Prostate Cancer
    Interventions
    Abiraterone acetate; Prednisolone; Goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-05
    Completion
    2024-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAbiraterone acetate; Prednisolone; Goserelin
    PhasePhase 2
    Registry statusUnknown

  • RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

    NCT04597125 · start 2020-11-09

    Registered record
    Registry ID
    NCT04597125
    Conditions
    Metastatic Castrate Resistant Prostate Cancer (mCRPC)
    Interventions
    Radium-223 dichloride (Xofigo, BAY88-8223); ARPI therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2020-11-09
    Completion
    2026-10-12
    Enrolment
    654

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castrate Resistant Prostate Cancer (mCRPC)
    InterventionRadium-223 dichloride (Xofigo, BAY88-8223); ARPI therapy
    PhasePhase 4
    Registry statusActive not recruiting